

Paper No. ___
Date: April 23, 2014

Filed on behalf of: NOVARTIS and LTS

By: Raymond R. Mandra
rmandra@fchs.com
(212) 218-2100

Nicholas N. Kallas
nkallas@fchs.com
(212) 218-2100

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

NOVEN PHARMACEUTICALS, INC.

Petitioner,

v.

NOVARTIS AG and LTS LOHMANN THERAPIE-SYSTEME AG,
Patent Owners.

Case IPR2014-00549
U.S. Patent No. 6,316,023

PATENT OWNERS'
MANDATORY NOTICES UNDER 37 C.F.R. § 42.8(a)(2)

1. Real Party-in-Interest Pursuant to 37 C.F.R. § 42.8(b)(1)

Pursuant to the requirements of 37 C.F.R. § 42.8(a)(2), the undersigned states that Novartis AG (“Novartis”) and LTS Lohmann Therapie-Systeme AG (formerly LTS Lohmann Therapie-Systeme GmbH Co. KG) (“LTS”) are the Patent Owners and real parties-in-interest in IPR2014-00549 directed to U.S. Patent No. 6,316,023 (“the ‘023 Patent”).

2. Related Matters Pursuant to 37 C.F.R. § 42.8(b)(2)

The ’023 Patent is being asserted in the following patent infringement lawsuits: (1) Novartis Pharm. Corp. et al. v. Par Pharm. Inc. et al., 1:11-cv-01077 (D. Del.); (2) Novartis Pharm. Corp. et al. v. Watson Labs. Inc. et al., No. 1:11-cv-01112 (D. Del.); (3) Novartis Pharm. Corp. et al. v. Alvogen Pine Brook Inc. et al., 1:13-cv-00052 (D. Del.); (4) Novartis Pharm. Corp. et al. v. Alvogen Pine Brook Inc. et al., 1:13-cv-00370 (D. Del.); (5) Novartis Pharm. Corp. et al. v. Actavis, Inc. et al., No. 1:13-cv-00371 (D. Del.); (6) Novartis Pharm. Corp. et al. v. Noven Pharm. Inc., 1:13-cv-00527 (D. Del.); and (7) Novartis Pharm. Corp. et al. v. Noven Pharm. Inc., 1:14-cv-00111 (D. Del.).

3. Identification of Lead and Back-Up Counsel Pursuant to 37 C.F.R. §§ 42.8(b)(3) and 42.10

Pursuant to 37 C.F.R. §§ 42.8(b)(3) and 42.10, Novartis and LTS designate Raymond R. Mandra (Reg. No. 34,382) as lead counsel and Nicholas N. Kallas (Reg. No. 31,530) as back-up counsel.

A power of attorney from each Patent Owner is being submitted with this Notice.

4. Service Information Pursuant to 37 C.F.R. § 42.8(b)(4)

Novartis and LTS may be served electronically using the following email address:

ExelonPatchIPR@fchs.com

Novartis and LTS may be served by postal mailing, hand-delivery, telephone or facsimile as follows:

Raymond R. Mandra
Fitzpatrick Cella, Harper & Scinto
1290 Avenue of the Americas
New York, NY 10104
Telephone: (212) 218-2100
Facsimile: (212) 218-2200

Respectfully submitted,

Dated: April 23, 2014

/Raymond R. Mandra/
Raymond R. Mandra (Reg. No. 34,382)
Lead Counsel for Patent Owner
Fitzpatrick, Cella, Harper & Scinto
1290 Avenue of the Americas
New York, NY 10104-3800
Tel. (212) 218-2100
Fax. (212) 218-2200
rmandra@fchs.com

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

NOVEN PHARMACEUTICALS, INC.

Petitioner,

v.

NOVARTIS AG and LTS LOHMANN THERAPIE-SYSTEME AG,
Patent Owners.

Case IPR2014-00549

U.S. Patent No. 6,316,023

CERTIFICATE OF SERVICE

The undersigned hereby certifies that Novartis AG And LTS Lohmann Therapie-Systeme AG's Mandatory Notices under 37 C.F.R. § 42.8(a)(2) in connection with IPR2014-00549 were served on this 23rd day of April 2014 using electronic mail, sent to the following email addresses:

Steven J. Lee (slee@kenyon.com); and
Cynthia Lambert Hardman (chardman@kenyon.com).

/Raymond R. Mandra/